Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326

Benzinga · 1d ago
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.